Report: Midcap biotechs boost R&D investment in Q3 2012

03/8/2013 | American City Business Journals

Midcap biotech companies spent $746.8 million on research and development in the third quarter of 2012, an increase from $621.1 million in the same period of 2011, according to a report from GlobalData. The focus of research programs is cancer treatment, "which is driving peer group R&D expenses higher," an analyst said.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC